Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7752W HIGH $12.15
Volume
27.86 K
Value Traded
110.98 K
Short % Float
0.8%
-2.54%Week
-0.97%1 Month
+1.66%3 Month
-25.85%6 Month
-98.88%5 Year
-99.18%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
25.60 M
EPS (TTM)
-1.38
P/E Ratio
-
Ent. Value
15.59 M
Total Shares
8.34 M
Float Shares
6.74 M
Insiders
19.22%
Institutions
6.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
EVAX Catalyst Timeline
Dated clinical, regulatory and corporate events for Evaxion A/S
Catalyst Timeline
Dated clinical, regulatory & corporate events for Evaxion A/S
183Total events
18Upcoming
32Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Preclinical PoCPreclinical
Evaxion begins applying AI-Immunology™ platform in autoimmune diseases
autoimmune diseasessource ↗
●Preclinical PoCPreclinical
Evaxion begins experimental testing of two AI-Immunology-based autoimmune disease treatment concepts
autoimmune diseasessource ↗
▲Pipeline PrioritizationEVX-05Corporate
Expansion of R&D pipeline with EVX-05 for glioblastoma
glioblastomasource ↗
●Development Candidate NominationEVX-05Preclinical
EVX-05 program announced and lead candidate optimization underway
glioblastomasource ↗
◆Poster PresentationEVX-V1Presentation
Poster presentation of new preclinical data for EVX-V1 at International Herpesvirus Workshop 2026
cytomegalovirus (CMV) infectionsource ↗
▲Poster PresentationEVX-V1Presentation
New data for EVX-V1 presented at International Herpesvirus Workshop 2026
cytomegalovirus (CMV)source ↗
◆Poster PresentationEVX-04Presentation
Poster presentation at EHA 2026 Congress
acute myeloid leukemiasource ↗
▲Oral PresentationPresentation
Evaxion receives Prix Galien UK Award for Best digital health solution for AI-Immunology platform
▲Preclinical PoCEVX-04Preclinical
New preclinical data demonstrating EVX-04 expression, secretion, immune recognition, and targeted cell-killing
acute myeloid leukemiasource ↗
▲Platform ValidationPreclinical
Won 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™
▲Management ChangeCorporate
Promotion of Birgitte Rønø to Chief Scientific and Chief Operating Officer
◆Poster PresentationPresentation
Poster presentation at AACR Annual Meeting on ERV-derived neoantigens for glioblastoma vaccine
glioblastomasource ↗
◆Poster PresentationEVX-01Presentation
Poster presentation of EVX-01 data at AACR 2026
advanced melanomasource ↗
▲Last Patient Last VisitEVX-01Trial
Last patient visit in one-year extension of phase 2 trial
advanced melanomasource ↗
◆Oral PresentationEVX-V1Presentation
Presentation of AI-powered target discovery for novel CMV vaccine (EVX-V1) at World Vaccine Congress
Cytomegalovirus (CMV)source ↗
◆IND SubmissionEVX-04IND
Planned clinical trial application submission for EVX-04
acute myeloid leukemiasource ↗
◆Full ResultsEVX-01Clinical Data
Three-year clinical efficacy data expected to be presented
advanced melanomasource ↗
◆Oral PresentationPresentation
Presentation of novel AI-based polio vaccine design concepts at World Vaccine Congress
poliosource ↗
▲Oral PresentationEVX-01Presentation
Presentation of immunogenicity data at AACR 2026
advanced melanomasource ↗
▲Last Patient Last VisitEVX-01Trial
Last patient last physician visit in one-year extension of Phase 2 trial
advanced melanomasource ↗
▲Poster PresentationEVX-04Presentation
New data for EVX-04 presented at EHA 2026 Congress
acute myeloid leukemia (AML)source ↗
▲Pipeline PrioritizationEVX-05Corporate
EVX-05 program expansion for glioblastoma
glioblastomasource ↗
▼Partnership / LicenseEVX-B2Corporate
MSD will not exercise option for EVX-B2; Evaxion retains global rights
Gonorrheasource ↗
▲Oral PresentationEVX-04Presentation
Oral presentation of EVX-04 preclinical data at ASH Annual Meeting
acute myeloid leukemiasource ↗
▲Oral PresentationEVX-04Presentation
Oral presentation at ASH 2025
acute myeloid leukemia (AML)source ↗
◆Management ChangeCorporate
Dr Helen Tayton-Martin appointed as new CEO, effective November 24, 2025
▲Preclinical PoCEVX-V1Preclinical
Positive data for lead antigens in CMV vaccine program EVX-V1 demonstrating protective effects
cytomegalovirus (CMV) infectionsource ↗
◆Poster PresentationEVX-01Presentation
Poster presentation of new immune data from phase 2 trial of EVX-01 at SITC 2025
advanced melanomasource ↗
▲Development Candidate NominationEVX-04Preclinical
Selection of EVX-04 as lead candidate for ERV-based precision cancer vaccine
acute myeloid leukemiasource ↗
◆Oral PresentationEVX-01Presentation
Webinar featuring KOL Dr. Muhammad Adnan Khattak discussing two-year phase 2 data
advanced melanomasource ↗
◆Oral PresentationEVX-01Presentation
Oral presentation of two-year clinical efficacy, immunogenicity and safety data from phase 2 trial of EVX-01 at ESMO Congress 2025
advanced melanomasource ↗
▲Full ResultsEVX-01Clinical Data
Two-year phase 2 data for EVX-01 showing 75% ORR
advanced melanomasource ↗
◆Oral PresentationEVX-01Presentation
Two-year clinical efficacy data from phase 2 trial of EVX-01 presented at ESMO 2025
advanced melanomasource ↗
◆Partnership / LicenseCorporate
Ambition to enter at least one more partnership deal in coming months
▲Oral PresentationEVX-01Presentation
Oral presentation of EVX-01 two-year data at ESMO conference
advanced melanomasource ↗
◆Reverse Stock SplitCorporate
Extraordinary General Meeting to approve share capital reduction and reverse stock split
Past FDA Catalysts and PDUFA Decisions
How EVAX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-12 | EVX-V1 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 69%
Micro Cap(rank 456 of 660)
Percentile Rank
Evaxion A/S faces pipeline headwinds (30/100), with $103M risk-adjusted pipeline value, led by EVX-01 in Melanoma Stage IV (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EVX-01 Small moleculeNCT05309421 | Melanoma Stage IV | Phase 2 | ACTIVE NOT_RECRUITING | 17 | Mar 30, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every EVAX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| EVX-01 | advanced melanoma | Phase 2 | 2026-10-02 | 75%, 12 out of 16 patients, 4 patients obtaining a complete response, 92%Read More | Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EVAX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in EVAX for Q2 2026. | ||||
EVAX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EVAX ranks across every disease it competes in
Competitive Position is a premium feature
See how EVAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEVAX News
EVAXEvaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Evaxion A/S will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The data, derived from a phase 2 trial, highlights the vaccine's systemic immunomodulatory effects when combined with pembrolizumab in advanced melanoma patients. The findings will be shared through both oral and poster presentations.
Read more →EVAXEvaxion applies its AI-Immunology™ platform in autoimmune diseases
Evaxion A/S is applying its AI-Immunology™ platform to develop treatments for autoimmune diseases, addressing a significant unmet medical need. The company is testing two novel concepts: a tolerogenic vaccine and an autoantibody binder. Initial data will be presented at the upcoming Protein & Antibody Engineering Summit in Lisbon on November 18, 2026.
Read more →EVAXEvaxion announces business update and second quarter 2026 financial results
Evaxion A/S has provided a business update and financial results for Q2 2026, highlighting significant advancements in its R&D pipeline, including upcoming presentations of clinical data for its cancer vaccine candidates. The company has been recognized for its AI-Immunology platform, winning the 2026 Prix Galien UK Award. Despite a net loss of $3.7 million, Evaxion maintains a cash runway into the second half of 2027.
Read more →EVAX▼ -6.3%on this newsshared move
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
Evaxion A/S has announced the expansion of its R&D pipeline with EVX-05, an AI-designed vaccine targeting glioblastoma. This off-the-shelf therapeutic vaccine aims to address the significant unmet medical needs in treating this aggressive brain cancer. The company is collaborating with Duke University for initial clinical testing, while maintaining a robust cash runway into 2027 despite discontinuing the EVX-03 program.
Read more →EVAXEvaxion to announce business update and second quarter 2026 financial results on August 20, 2026
Evaxion A/S will announce its business update and second quarter 2026 financial results on August 20, 2026. The company will host a conference call and webcast at 14:30 CET/08:30 EST to present the results and answer questions. Evaxion focuses on developing novel vaccines using its AI-Immunology platform, addressing significant medical needs.
Read more →EVAXEvaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
Evaxion A/S will present three-year clinical efficacy data for its personalized cancer vaccine EVX-01 at the ESMO Congress 2026. This data, stemming from a phase 2 trial, will provide insights into the vaccine's effects as a stand-alone treatment for advanced melanoma. Previous two-year results showed a 75% objective response rate and significant durability of responses.
Read more →EVAXEvaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
Evaxion A/S presented promising preclinical data for its cytomegalovirus vaccine program EVX-V1 at the International Herpesvirus Workshop 2026. The data indicates that the vaccine could improve control of CMV infections through a multi-component approach that utilizes AI-discovered antigens. This advancement is crucial as CMV poses significant health risks, particularly to immunocompromised individuals and infants.
Read more →EVAXEvaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
Evaxion A/S will present new preclinical data for its cytomegalovirus vaccine candidate, EVX-V1, at the International Herpesvirus Workshop in Montreal. The data will aid in the final selection of antigens for the vaccine, which combines novel AI-discovered and optimized components. This innovative approach aims to enhance the vaccine's protective potential against CMV.
Read more →EVAXEvaxion receives Prix Galien UK Award for Best digital health solution
Evaxion A/S has been awarded the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology™ platform. This recognition highlights the platform's capabilities in developing novel vaccines for cancer and infectious diseases. The award was presented to CEO Helen Tayton-Martin at a ceremony in London, marking a significant achievement for the company.
Read more →EVAXEvaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
Evaxion A/S has announced promising preclinical data for its therapeutic vaccine EVX-04, targeting acute myeloid leukemia (AML). The vaccine is shown to be effectively expressed and secreted in human cells, driving specific immune responses that mediate targeted cell-killing. This data will be presented at the EHA 2026 Congress, highlighting its potential as a novel treatment option for AML patients.
Read more →EVAXEvaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
Evaxion A/S will present new preclinical data for EVX-04, a therapeutic vaccine for acute myeloid leukemia (AML), at the EHA 2026 Congress in Stockholm. The data will focus on the functional characterization of EVX-04, which targets specific tumor antigens. The company plans to submit a clinical trial application later in 2026.
Read more →EVAX▼ -7.7%on this newsshared move
Evaxion announces business update and first quarter 2026 financial results
Evaxion A/S reported a positive business update alongside its Q1 2026 financial results, highlighting significant advancements in its AI-Immunology™ platform. The company achieved an 86% vaccine target recognition rate for its personalized cancer vaccine, EVX-01, and successfully extended its phase 2 trial. Additionally, Evaxion is developing new polio vaccine concepts in collaboration with The Gates Foundation. Despite a net loss increase, the company maintains a cash runway into 2027.
Read more →EVAXEvaxion to announce business update and first quarter 2026 financial results on May 7, 2026
Evaxion A/S will announce a business update and its first quarter 2026 financial results on May 7, 2026. The company, known for its AI-Immunology™ platform, will host a conference call and webcast to present these updates. The event aims to engage stakeholders and provide insights into Evaxion's ongoing projects.
Read more →EVAXEvaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
Evaxion A/S has promoted Birgitte Rønø to the dual role of Chief Scientific Officer and Chief Operating Officer. This change aims to enhance the company's strategy execution and external visibility of its AI-Immunology™ platform. Rønø's extensive contributions to the company were acknowledged in this decision, which is expected to strengthen Evaxion's capabilities in vaccine development.
Read more →EVAX▲ +7.5%on this news
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
Evaxion A/S has announced new data showcasing its AI-Immunology™ platform's capability to develop vaccines for glioblastoma. The platform identifies endogenous retrovirus-derived antigens, which could significantly improve vaccine efficacy for this challenging cancer. The findings will be presented at the upcoming AACR Annual Meeting, highlighting the potential of AI in cancer treatment.
Read more →EVAX▲ +7.5%on this news
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
Evaxion A/S has reported promising phase 2 trial results for its personalized cancer vaccine EVX-01, demonstrating an 86% success rate in triggering tumor-specific immune responses. The data, which will be presented at the AACR Annual Meeting, highlights the effectiveness of Evaxion's AI-Immunology™ platform in identifying relevant vaccine targets. The trial also showed durable immune responses and a strong correlation between AI predictions and immune response magnitude.
Read more →EVAXEvaxion concludes Annual General Meeting
Evaxion A/S held its Annual General Meeting on April 16, 2026, where the 2025 Annual Report was approved, and several board members were re-elected. The meeting highlighted the company's commitment to developing novel vaccines through its AI-Immunology™ platform. Contact information for investor relations was also provided.
Read more →EVAXEvaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01
Evaxion A/S has completed a one-year extension of its phase 2 trial for the personalized cancer vaccine EVX-01. The trial yielded promising results, including a 75% Objective Response Rate and sustained responses in patients. The three-year clinical efficacy data is expected to be presented in the second half of 2026, further enhancing the data package for EVX-01.
Read more →EVAX▲ +7.1%on this news
Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
Evaxion A/S has developed innovative polio vaccine design concepts using its AI-Immunology™ platform, in collaboration with the Gates Foundation. These concepts aim to improve upon existing vaccines and will be presented at the World Vaccine Congress. Additionally, Evaxion will showcase data from its EVX-V1 program targeting cytomegalovirus.
Read more →About Evaxion A/S
BIOPHARMAWATCH ELITE PLUS
Trade the next EVAX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime